Eligo Bioscience

Headquarters: Paris
Employees: 11–50
Founded: 2014
Business Model: B2B

Website: eligo-bioscience.com
Total Funding: $57.5M
Last Round: $5.0M GrantMay 2025

About

Eligo Bioscience is a clinical-stage biotechnology company developing in vivo gene editing medicines that precisely target the microbiome. Their proprietary GEM (Gene Editing of the Microbiome) platform uses phage-derived delivery systems to edit bacterial genes inside the body, enabling precision treatment of diseases in oncology, inflammation, and autoimmunity driven by specific microbial gene expression.

LinkedIn X (Twitter)GitHub

Sign up to view funding chart

Create a free account to see funding visualizations and detailed round data.

Create Free Account

Funding History

Sign up to view funding details

Create a free account to see full funding history, valuations, and investor participation.

Create Free Account

Investors

Sign up to view investors

Create a free account to see which investors have funded this company.

Create Free Account